Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Interventional × Malignant Disease × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4950 Neoplasms 4148 Prostatic Neoplasms 2412 Carcinoma, Non-Small-Cell Lung 2245 Colorectal Neoplasms 2025 Lung Neoplasms 1692 Multiple Myeloma 1446 Lymphoma 1398 Leukemia, Myeloid, Acute 1368 Neoplasm Metastasis 1361 Melanoma 1263 Pancreatic Neoplasms 1193 Leukemia 1193 Ovarian Neoplasms 1185 Lymphoma, Non-Hodgkin 1123 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1084 Head and Neck Neoplasms 1041 Leukemia, Lymphocytic, Chronic, B-Cell 993 Lymphoma, Follicular 893 Colonic Neoplasms 888 Brain Neoplasms 870 Stomach Neoplasms 847 Recurrence 844 Carcinoma, Hepatocellular 836 Glioblastoma 833 Lymphoma, Large B-Cell, Diffuse 767 Rectal Neoplasms 754 Uterine Cervical Neoplasms 719 Carcinoma, Renal Cell 699 Hodgkin Disease 693

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡